NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

This study checked how much of a high-dose eye medication gets into the bloodstream when injected into both eyes. Researchers gave 51 adults with diabetic macular edema or age-related macular degeneration injections in both eyes and measured drug levels in their blood. The goal w…

This study tested whether a new medication called LUBT010 works as well as the established drug Lucentis for treating wet age-related macular degeneration, a leading cause of vision loss in older adults. 600 participants aged 50+ with active vision loss received monthly eye injec…

This first-in-human study tested the safety of a new eye injection called PMC-403 for wet age-related macular degeneration (AMD), a major cause of vision loss. It involved 17 participants with wet AMD whose vision was still declining despite standard treatments. The main goal was…

This was a first-in-human study to check the safety of a new drug, OLX10212, for wet age-related macular degeneration (AMD). It involved 21 patients who received injections of the drug into their eye. The main goal was to see if the treatment was safe and tolerable, while also lo…

This study aimed to check the long-term safety of a drug called faricimab for people with wet age-related macular degeneration, a leading cause of vision loss. Over 1,000 patients who had already completed earlier studies received the drug via eye injections at personalized inter…

This completed Phase 3 study tested whether a new, potentially more affordable biosimilar version of the drug aflibercept (FYB203) works as well and is as safe as the established drug Eylea for treating wet age-related macular degeneration (AMD). The study involved 434 patients w…

This study measured the thickness of eye tissues in people with two common vision conditions (neovascular age-related macular degeneration and diabetic macular edema) and compared them to healthy people. Researchers used a special imaging machine to take detailed pictures of the …